- Home
- IMNN
IMNN
Imunon Inc.
as 06-05-2025 4:00pm EST
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).
| Founded: | 1982 | Country: | United States |
| Employees: | N/A | City: | LAWRENCEVILLE |
| Market Cap: | 12.1M | IPO Year: | 1985 |
| Target Price: | $14.00 | AVG Volume (30 days): | 31.3M |
| Analyst Decision: | Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.39 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.37 - $3.65 | Next Earning Date: | 05-12-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Imunon Inc. News
IMNN Breaking Stock News: Dive into IMNN Ticker-Specific Updates for Smart Investing
GlobeNewswire
a day ago
IMUNON to Present at the Zacks SCR Life Sciences Virtual Investor Forum on June 12th
Clinical Trials Arena
2 days ago
ASCO25: Imunon shares positive results from trial of IMNN-001 for ovarian cancer
GlobeNewswire
3 days ago
IMUNON Announces Data Presented at ASCO Reinforces Unprecedented Overall Survival in Ovarian Cancer Phase 2 Study
GlobeNewswire
4 days ago
IMUNON CEO RECAPS A YEAR OF CLINICAL ACHIEVEMENT AND SOLID FUNDAMENTALS
Zacks Small Cap Research
4 days ago
IMNN: Momentum Continues with Presentations at ASCO and ESMO Gynaecological Cancers…
Insider Monkey
8 days ago
Imunon, Inc. (IMNN) Raises $3.25M in Private Placement, Eyes $6.5M More
MT Newswires
9 days ago
Imunon Closes Private Placement of Shares, Warrants to Raise Up to $9.75 Million
GlobeNewswire
9 days ago
IMUNON Closes Up To $9.75 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Compare IMNN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IMNN Imunon Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.